Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and birb 796

sorafenib has been researched along with birb 796 in 18 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(birb 796)		Trials
(birb 796)		Recent Studies (post-2010) (birb 796)
6,5207305,251137580

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)birb 796 (IC50)
Mitogen-activated protein kinase 13Homo sapiens (human)0.1057
Mitogen-activated protein kinase kinase kinase 7Homo sapiens (human)0.9
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)10
Serine/threonine-protein kinase 10Homo sapiens (human)1
Mitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)1
Epidermal growth factor receptorHomo sapiens (human)3.8
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)1.4
High affinity nerve growth factor receptorHomo sapiens (human)0.58
Heat shock protein beta-1Homo sapiens (human)0.058
Protein kinase C beta typeHomo sapiens (human)6.9
Tyrosine-protein kinase LckHomo sapiens (human)2.1
Tyrosine-protein kinase YesHomo sapiens (human)8.9
Tyrosine-protein kinase LynHomo sapiens (human)0.96
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.515
Tyrosine-protein kinase HCKHomo sapiens (human)1.7
Platelet-derived growth factor receptor betaHomo sapiens (human)6.2
Tyrosine-protein kinase FgrHomo sapiens (human)8.5
Mast/stem cell growth factor receptor KitHomo sapiens (human)1
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.0834
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.625
Ephrin type-A receptor 1Homo sapiens (human)0.63
Fibroblast growth factor receptor 4Homo sapiens (human)7
Mitogen-activated protein kinase 1Homo sapiens (human)9.2
Ephrin type-A receptor 2Homo sapiens (human)0.16
Ephrin type-A receptor 3Homo sapiens (human)1.1
Ephrin type-A receptor 8Homo sapiens (human)1
Ephrin type-B receptor 2Homo sapiens (human)0.58
Tyrosine-protein kinase receptor Tie-1Homo sapiens (human)1
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.27
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.34
Tyrosine-protein kinase FRKHomo sapiens (human)1
Mitogen-activated protein kinase 8Homo sapiens (human)1
Mitogen-activated protein kinase 9Homo sapiens (human)0.2989
Cyclin-dependent kinase 8Homo sapiens (human)1
Glycogen synthase kinase-3 betaHomo sapiens (human)1.06
Tyrosine-protein kinase BlkHomo sapiens (human)1
Mitogen-activated protein kinase 12Homo sapiens (human)0.2298
Mitogen-activated protein kinase 10Homo sapiens (human)1.2
Ephrin type-B receptor 3Homo sapiens (human)9.4
Ephrin type-A receptor 5Homo sapiens (human)0.09
Ephrin type-B receptor 4Homo sapiens (human)0.9
Ephrin type-B receptor 1Homo sapiens (human)0.11
Ephrin type-A receptor 4Homo sapiens (human)0.07
Cyclin-dependent-like kinase 5 Homo sapiens (human)1
Angiopoietin-1 receptorHomo sapiens (human)0.5125
Focal adhesion kinase 1Homo sapiens (human)2
Protein kinase C delta typeHomo sapiens (human)1.9
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)1
Protein-tyrosine kinase 2-betaHomo sapiens (human)0.7
Ephrin type-A receptor 7Homo sapiens (human)1
TGF-beta-activated kinase 1 and MAP3K7-binding protein 1Homo sapiens (human)0.9
Mitogen-activated protein kinase 11Homo sapiens (human)0.256
NT-3 growth factor receptorHomo sapiens (human)1
Mitogen-activated protein kinase 14Homo sapiens (human)0.0674
BDNF/NT-3 growth factors receptorHomo sapiens (human)0.525
Discoidin domain-containing receptor 2Homo sapiens (human)0.2707
Misshapen-like kinase 1Homo sapiens (human)0.04
STE20-like serine/threonine-protein kinase Homo sapiens (human)1
Mitogen-activated protein kinase kinase kinase 20Homo sapiens (human)1
TRAF2 and NCK-interacting protein kinaseHomo sapiens (human)1
Serine/threonine-protein kinase MRCK betaHomo sapiens (human)1

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (27.78)29.6817
2010's12 (66.67)24.3611
2020's1 (5.56)2.80

Authors

AuthorsStudies
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP1
Knight, ZA; Shokat, KM1
Gray, NS; Liu, Y1
Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N1
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Getlik, M; Grütter, C; Klüter, S; Naqvi, T; Pawar, V; Rabiller, M; Rauh, D; Simard, JR1
Dietrich, J; Hulme, C; Hurley, LH1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Russu, WA; Shallal, HM1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Beck, ME; Braun, CA; Getlik, M; Grütter, C; Gutbrod, O; Mayer-Wrangowski, SC; Pérez-Martín, J; Rauh, D; Richters, A; Schreier, PH; Simard, JR1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Engel, J; Grütter, C; Nguyen, HD; Phan, T; Rauh, D; Richters, A; Simard, JR1
Ding, K; Li, Y; Lu, X; Ren, X1
Alder, J; Benitez, R; Davidson, C; Davies, MP; Hayes, JM; Jakupovic, S; Martinez, A; Perez, C; Rzepecka, K; Welsby, P1
Bukhtiyarova, M; Karpusas, M; Lee, Y; Namboodiri, HV; Ramcharan, J; Springman, EB1
Liu, H; Shen, Y; Yang, Y; Yao, X1
Eriksson, LA; Gao, C; Grøtli, M1

Reviews

2 review(s) available for sorafenib and birb 796

ArticleYear
Features of selective kinase inhibitors.
    Chemistry & biology, 2005, Volume: 12, Issue:6

    Topics: Animals; Drug Evaluation, Preclinical; Humans; Phosphoric Monoester Hydrolases; Protein Kinase Inhibitors; Substrate Specificity

2005
Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
    Journal of medicinal chemistry, 2015, Apr-23, Volume: 58, Issue:8

    Topics: Amino Acid Sequence; Animals; Discoidin Domain Receptors; Drug Discovery; Humans; Inflammation; Ligands; Models, Molecular; Molecular Sequence Data; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Small Molecule Libraries

2015

Other Studies

16 other study(ies) available for sorafenib and birb 796

ArticleYear
A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nature biotechnology, 2005, Volume: 23, Issue:3

    Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines

2005
Rational design of inhibitors that bind to inactive kinase conformations.
    Nature chemical biology, 2006, Volume: 2, Issue:7

    Topics: Binding Sites; Drug Design; Humans; Models, Molecular; Phosphotransferases; Protein Kinase Inhibitors; Protein Structure, Tertiary

2006
The selectivity of protein kinase inhibitors: a further update.
    The Biochemical journal, 2007, Dec-15, Volume: 408, Issue:3

    Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera

2007
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Displacement assay for the detection of stabilizers of inactive kinase conformations.
    Journal of medicinal chemistry, 2010, Jan-14, Volume: 53, Issue:1

    Topics: Crystallography, X-Ray; Drug Design; Mitogen-Activated Protein Kinase 9; Models, Molecular; p38 Mitogen-Activated Protein Kinases; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship; Urea

2010
The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
    Bioorganic & medicinal chemistry, 2010, Aug-01, Volume: 18, Issue:15

    Topics: Adenosine Triphosphate; Allosteric Regulation; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Benzenesulfonates; Catalytic Domain; Computer Simulation; Crystallography, X-Ray; Drug Design; Hydrogen Bonding; Imatinib Mesylate; Mitogen-Activated Protein Kinase 14; Naphthalenes; Niacinamide; Oligopeptides; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-abl; Pyrazoles; Pyridines; Pyrimidines; Sorafenib

2010
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Targeting GSK3 from Ustilago maydis: type-II kinase inhibitors as potential antifungals.
    ACS chemical biology, 2012, Jul-20, Volume: 7, Issue:7

    Topics: Amino Acid Sequence; Antifungal Agents; Crystallography, X-Ray; Drug Delivery Systems; Glycogen Synthase Kinase 3; Humans; Molecular Sequence Data; Protein Kinase Inhibitors; Ustilago

2012
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Identification of type II and III DDR2 inhibitors.
    Journal of medicinal chemistry, 2014, May-22, Volume: 57, Issue:10

    Topics: Discoidin Domain Receptors; Drug Design; Fluorescence; High-Throughput Screening Assays; Ligands; Protein Kinase Inhibitors; Protein Structure, Tertiary; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Structure-Activity Relationship

2014
Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase-3β.
    Journal of medicinal chemistry, 2021, 02-11, Volume: 64, Issue:3

    Topics: Cell Line, Tumor; Drug Design; Enzyme Inhibitors; Glycogen Synthase Kinase 3 beta; Humans; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Neuroprotective Agents; Phosphorylation; Structure-Activity Relationship; Substrate Specificity; tau Proteins

2021
Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
    Biochemistry, 2010, May-04, Volume: 49, Issue:17

    Topics: Benzamides; Benzenesulfonates; Crystallography, X-Ray; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinase 14; Models, Molecular; Molecular Structure; Naphthalenes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-abl; Pyrazoles; Pyridines; Pyrimidines; Sorafenib; Structure-Activity Relationship

2010
Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
    Journal of chemical information and modeling, 2011, Dec-27, Volume: 51, Issue:12

    Topics: Allosteric Regulation; Benzamides; Benzenesulfonates; Catalytic Domain; Humans; Imatinib Mesylate; Indenes; Mitogen-Activated Protein Kinase 14; Molecular Dynamics Simulation; Naphthalenes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Sorafenib; Thermodynamics

2011
Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
    Journal of molecular modeling, 2015, Volume: 21, Issue:7

    Topics: Aminopyridines; Binding Sites; Humans; Indoles; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Naphthalenes; Niacinamide; Oligonucleotides; Phenylurea Compounds; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Sorafenib; Structural Homology, Protein; Thermodynamics; Vascular Endothelial Growth Factor Receptor-2

2015